Rapid improvement in pain and neurologic dysfunction in severe chronic sciatica is carefully documented in the comfort of the TransBarrier® office setting. The rapid and gentle process does not require anesthesia. The patented off-label method of treatment utilized was invented at TransBarrier® where it has been used for more than a decade. Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. The method utilized for this indication is off-label.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. Treatment for this indication is off-label. Please see the Terms of Use. The method of treatment utilized is a patented invention of TransBarrier®.

Rapid improvement in pain and neurologic dysfunction in severe chronic sciatica is carefully documented in the comfort of the TransBarrier® office setting. The rapid and gentle process does not require anesthesia.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. Treatment for this indication is off-label. Please see the Terms of Use. The method of treatment utilized is a patented invention of TransBarrier®.

Patient responds to treatment at TransBarrier® in Los Angeles within minutes after 2 years of constant severe pain. Response to treatment at TransBarrier® has been documented in multiple, published, peer-reviewed scientific articles.

Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment for these indications is innovative (“off-label”). The method of off-label treatment utilized is a patented invention of TransBarrier®. Please see the Terms of Use.

Rapid clinical improvement 10 years after brain injury following treatment at TransBarrier® in Boca Raton, Florida. The patient and her parents flew from Australia to TransBarrier® to receive treatment.

Chronic neurological dysfunction produced by stroke and traumatic brain injury has long been thought to be irreversible. A new scientific discovery by TransBarrier®, as documented in the video above, now promises to change current thinking about the potential for recovery of function, even years after the acute event.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 TransBarrier®, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

Significant recovery of neurological function years after stroke, including improvement in gait, left hand function and verbal function is documented.

Chronic neurological dysfunction produced by stroke and traumatic brain injury has long been thought to be irreversible. A new scientific discovery by TransBarrier®, as documented in the video above, now promises to change current thinking about the potential for recovery of function, even years after the acute event.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 TransBarrier®, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

Clinical improvement following treatment at TransBarrier® in Boca Raton, Florida is documented.

Chronic neurological dysfunction produced by stroke and traumatic brain injury has long been thought to be irreversible. A new scientific discovery by TransBarrier®, as documented in the video above, now promises to change current thinking about the potential for recovery of function, even years after the acute event.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 TransBarrier®, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

Rapid neurological improvement after stroke following treatment at TransBarrier® is documented.

Chronic neurological dysfunction produced by stroke and traumatic brain injury has long been thought to be irreversible. A new scientific discovery by TransBarrier®, as documented in the video above, now promises to change current thinking about the potential for recovery of function, even years after the acute event.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 TransBarrier®, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

Clinical improvement following treatment at TransBarrier® is documented, eight years after stroke. For further information regarding additional patients please see Rapid improvement of chronic stroke deficits …: three consecutive cases. CNS Drugs. 2011 Feb;25(2):145-155.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 TransBarrier®, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, Australian patent 758523.

Rapid improvement in speech and motor function, two years after stroke following local anti-TNF administration at TransBarrier® is documented. Individual results can vary. Chronic neurological dysfunction produced by stroke has long been thought to be irreversible. A new scientific discovery by TransBarrier®, as documented in the video above, now promises to change current thinking about the potential for recovery of function, even years after the acute event.

This new patented treatment is available for new patients at TransBarrier®. For further information, please call TransBarrier® in Los Angeles at (310) 479-0107, or in Boca Raton at (561) 353-9707.

Please see: CNS Drugs. 2011 Feb;25(2):145-155.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 TransBarrier®, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

Patient, sons and wife discuss improvements following treatment at TransBarrier® in Los Angeles years after stroke.

Chronic neurological dysfunction produced by stroke and traumatic brain injury has long been thought to be irreversible. A new scientific discovery by TransBarrier®, as documented in the video above, now promises to change current thinking about the potential for recovery of function, even years after the acute event.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 TransBarrier®, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.